Beyang Closes Oversubscribed $30 Million Series A Financing

second-generation Menin inhibitornovel ophthalmic therapyPositive

AI Analysis

Summary

Beyang closed an oversubscribed $30 million Series A financing to advance its AI-driven ExCEED platform and clinical development of a second-generation Menin inhibitor and novel ophthalmic therapy.

Importance:5/10

Sentiment:

0.70

Series A financingAI platformMenin inhibitorophthalmic therapycapital raise

Related Companies

$GBIO $INTI $GBCYD $CHHE

Read the original article

Published by PR Newswire Clinical Trials on August 12, 2026 9:25 AM

Read Original